Clinical Trial

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

Study acronym: ASHA-1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-31; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2024-01-29
Trial Details
NCT Number NCT05984147
Lead Sponsor Aurigene Discovery Technologies Limited
Conditions Relapsed Advanced Lymphomas
Enrollment 40 participants
Start Date 2023-10-19
Primary Completion 2027-08-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-17